This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A et al. Effect of initial treatment strategy on survival of patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-analysis. Lancet Oncol 2013; 14: 943–952.
Specht L, Gray RG, Clarke MJ, Peto R . Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16: 830–843.
Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by fondazione italiana linfomi. J Clin Oncol 2016; 34: 1175–1181.
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484.
Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065–2071.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363: 1812–1821.
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311–319.
Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM et al. Hematopoietic progenitor cell harvesting is feasible after treatment with brentuximab vedotin in CD30(+) lymphoma patients who received multiple prior lines of treatment. Biol Blood Marrow Transplant 2015; 21: 1529–1531.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853–1862.
Wirk B, Storer BE, Maloney DG, Gopal AK, Cassaday RD, Salit R et al. Analysis of pre-transplant therapy with brentuximab vedotin for relapsed/refractory Hodgkin lymphoma on outcomes of reduced intensity conditioned allogeneic hematopoietic cell transplantation. Blood 2015; 126: 4406.
Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 2016; 34: 3733–3739.
Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016; 17: 1283–1294.
Merindol N, Champagne MA, Duval M, Soudeyns H . CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. Blood 2011; 118: 4480–4488.
Herbaux C, Gauthier J, Brice P, Fornecker L, Bouabdallah K, Manson G et al. Nivolumab is effective and reasonably safe in relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation: a study from the LYSA and SFGM-TC. Blood 2015; 126: 3979.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Paolo F. Caimi serves as speaker for Celgene. Hillard M. Lazarus serves as speaker for Bristol-Myers Squibb.
Rights and permissions
About this article
Cite this article
Covut, F., Pinto, R., Cooper, B. et al. Nivolumab before and after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 52, 1054–1056 (2017). https://doi.org/10.1038/bmt.2017.44
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2017.44
This article is cited by
-
Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma—a long-term follow-up single center experience
Annals of Hematology (2020)
-
Bleomycin
Reactions Weekly (2017)